These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35198504)

  • 21. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
    Bostom AG; Carpenter MA; Hunsicker L; Jacques PF; Kusek JW; Levey AS; McKenney JL; Mercier RY; Pfeffer MA; Selhub J;
    Am J Kidney Dis; 2009 Jan; 53(1):121-8. PubMed ID: 19022547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homocysteine and diabetes: Role in macrovascular and microvascular complications.
    Muzurović E; Kraljević I; Solak M; Dragnić S; Mikhailidis DP
    J Diabetes Complications; 2021 Mar; 35(3):107834. PubMed ID: 33419630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease.
    Sunder-Plassmann G; Winkelmayer WC; Födinger M
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2637-51. PubMed ID: 11060826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse myocardial effects of B-vitamin therapy in subjects with chronic kidney disease and hyperhomocysteinaemia.
    Rafeq Z; Roh JD; Guarino P; Kaufman J; Joseph J
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):836-42. PubMed ID: 22902185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The factors that affect plasma homocysteine levels, pulse wave velocity and their relationship with cardiovascular disease indicators in peritoneal dialysis patients.
    Ertek S; Torun AN; Ates K
    Int Urol Nephrol; 2010 Mar; 42(1):211-8. PubMed ID: 19653113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homocysteine and Non-Cardiac Vascular Disease.
    Katsiki N; Perez-Martinez P; Mikhailidis DP
    Curr Pharm Des; 2017; 23(22):3224-3232. PubMed ID: 28317478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperhomocysteinemia in end-stage renal failure.
    Kes P
    Acta Med Croatica; 2000; 54(4-5):175-81. PubMed ID: 11379482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study of the homocysteine status in children with chronic renal failure.
    Farid FA; Faheem MS; Heshmat NM; Shaheen KY; Saad SS
    Am J Nephrol; 2004; 24(3):289-95. PubMed ID: 15087588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
    Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
    JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
    Sjöberg B; Anderstam B; Suliman M; Alvestrand A
    Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hyperhomocysteinemia in chronic renal failure.].
    Satta E; Perna AF; Lombardi C; Acanfora F; Violetti E; Romano MM; Capasso R; Pisano M; Paduano F; De Santo NG
    G Ital Nefrol; 2006; 23(5):480-9. PubMed ID: 17123261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?
    De Vriese AS; Verbeke F; Schrijvers BF; Lameire NH
    Kidney Int; 2002 Apr; 61(4):1199-209. PubMed ID: 11918726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lowering homocysteine levels may prevent cardiovascular impairments? Possible therapeutic behaviors.
    Cacciapuoti F
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):677-9. PubMed ID: 23135377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Homocysteine, cysteine, folate and vitamin B₁₂ status in type 2 diabetic patients with chronic kidney disease.
    Pastore A; Noce A; Di Giovamberardino G; De Stefano A; Callà C; Zenobi R; Dessì M; Di Daniele N
    J Nephrol; 2015 Oct; 28(5):571-6. PubMed ID: 25095762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of vitamin-optimized plasma homocysteine cutoff values on the prevalence of hyperhomocysteinemia in healthy adults.
    Fokkema MR; Weijer JM; Dijck-Brouwer DA; van Doormaal JJ; Muskiet FA
    Clin Chem; 2001 Jun; 47(6):1001-7. PubMed ID: 11375284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fenofibrate, homocysteine and renal function.
    Foucher C; Brugère L; Ansquer JC
    Curr Vasc Pharmacol; 2010 Sep; 8(5):589-603. PubMed ID: 20507276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folic Acid Supplementation in Patients with Elevated Homocysteine Levels.
    Kaye AD; Jeha GM; Pham AD; Fuller MC; Lerner ZI; Sibley GT; Cornett EM; Urits I; Viswanath O; Kevil CG
    Adv Ther; 2020 Oct; 37(10):4149-4164. PubMed ID: 32845472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective homocysteine-lowering vitamin B treatment in peritoneal dialysis patients.
    Righetti M; Tommasi A; Lagona C; La Rosa L; Uccellini M; Sessa A
    Perit Dial Int; 2004; 24(4):373-7. PubMed ID: 15335152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the meaning of homocysteine in patients on dialysis?
    Silva de Almeida CC; Guerra DC; Vannucchi MT; Geleilete TJ; Vannucchi H; Chiarello PG
    J Ren Nutr; 2011 Sep; 21(5):394-400. PubMed ID: 21439851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between homocysteine level and vitamins B12, B9 and B6 status in patients with chronic kidney disease.
    Shevchuk SV; Postovitenko KP; Iliuk IA; Bezsmertna HV; Bezsmertnyi YO; Kurylenko IV; Biloshytska AV; Baranova IV
    Wiad Lek; 2019; 72(4):532-538. PubMed ID: 31055527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.